Department of Nursing, Gifu Kyoritsu University, Japan.
Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Japan.
J Viral Hepat. 2022 Oct;29(10):919-929. doi: 10.1111/jvh.13728. Epub 2022 Jul 9.
The risk factors for hepatocellular carcinoma (HCC) development in patients whose duration of sustained virological response (SVR) is over 10 years are not fully understood. We compared the incidence of HCC development within and beyond 10 years after SVR. A total of 1384 patients who achieved SVR (714, interferon-based therapy; 670, direct-acting antiviral therapy) were enrolled. Factors associated with HCC development were analysed within and beyond 10 years after SVR by Cox proportional hazards models. The annual incidence rates of HCC development were 0.568% within 10 years after SVR and 0.190% beyond 10 years, and there was a significant difference in the incidence of HCC development between the 2 periods (p = 0.0242, log-rank test). Male gender (adjusted hazard ratio [aHR] 2.930; 95% confidence interval [CI] 1.508-5.693, p = 0.0015), fibrosis-4 (FIB-4) score > 3.25 (aHR 4.364; 95%CI 2.206-8.633, p < 0.0001) and alpha-fetoprotein ≥5.0 ng/ml (aHR 2.381; 95%CI 1.325-4.280, p = 0.0037) were independently associated with HCC development within 10 years after SVR. Male gender (aHR 4.702; 95%CI 1.366-16.190, p = 0.0141), presence of diabetes mellitus (aHR 2.933; 95%CI 1.240-6.935, p = 0.0143) and gamma-glutamyl transpeptidase (GGT) ≥ 56 U/l (aHR 4.157; 95%CI 1.400-12.350, p = 0.0103) were independently associated with HCC development beyond 10 years after SVR. The incidence of HCC development beyond 10 years after SVR was very low, and the associated factors were mainly extrahepatic, including DM and elevated GGT. Annual routine check-ups with abdominal ultrasound may be sufficient for such patients. (242 words).
在持续病毒学应答(SVR)超过 10 年的患者中,肝细胞癌(HCC)发展的风险因素尚不完全清楚。我们比较了 SVR 后 10 年内和 10 年后 HCC 发展的发生率。共纳入 1384 例 SVR 患者(714 例,基于干扰素的治疗;670 例,直接作用抗病毒治疗)。通过 Cox 比例风险模型分析 SVR 后 10 年内和 10 年后与 HCC 发展相关的因素。SVR 后 10 年内 HCC 发展的年发生率为 0.568%,10 年后为 0.190%,两个时期的 HCC 发展发生率有显著差异(p=0.0242,对数秩检验)。男性(调整后的危险比[aHR]2.930;95%置信区间[CI]1.508-5.693,p=0.0015)、纤维化-4(FIB-4)评分>3.25(aHR 4.364;95%CI 2.206-8.633,p<0.0001)和甲胎蛋白(AFP)≥5.0ng/ml(aHR 2.381;95%CI 1.325-4.280,p=0.0037)与 SVR 后 10 年内 HCC 发展独立相关。男性(aHR 4.702;95%CI 1.366-16.190,p=0.0141)、糖尿病(aHR 2.933;95%CI 1.240-6.935,p=0.0143)和谷氨酰转肽酶(GGT)>=56U/l(aHR 4.157;95%CI 1.400-12.350,p=0.0103)与 SVR 后 10 年以上 HCC 发展独立相关。SVR 后 10 年以上 HCC 发展的发生率非常低,相关因素主要为肝外因素,包括 DM 和升高的 GGT。对于此类患者,每年进行腹部超声常规检查可能就足够了。(242 个单词)